Effects of maternal serum on permeability of glomerular endothelial cell membrane

Abstract

The mechanism of injury on the human glomerular endothelial cells (ciGENC) induced by preeclampsia serum was investigated. Concentration of maternal serum sFlt-1 protein was detected by ELISA. Fluorescently-labeled bovine serum albumin infiltrating through lower chamber of Transwell was measured by multifunction microplate reader. Morphologic change of ciGENC was observed under inverted phase contrast microscope. The concentration of sflt-1 in preeclampsia groups was significantly increased as compared with control group (P<0.01). Permeability in preeclampsia groups was significantly increased as compared with control group (P<0.01). By contrast with severe preeclampsia group, the permeability of ciGENC monolayer in mild preeclampsia group was decreased significantly (P<0.05). Intervention of exogenous VEGF significantly decreased permeability of ciGENC in preeclampsia groups. It was concluded that sFlt-1 increased ciGENC permeability by damaging integrity of endothelial barrier function.

Keywords

preeclampsia / serum / glomerular endothelial cells / permeability / sFlt-1 / VEGF

References

[1] SibaiB., DekkerG., KupfermincM., et al.. Preeclampsia. Lancet, 2005, 365(9461): 785-799

[2] LorquetS., PequeuxC., MunautC., et al.. Aetiology and physiopathology of preeclampsia and related forms. Acta Clin Belg, 2010, 65(4): 237-241

[3] MyersJ., MiresG., MacleodM., et al.. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension, 2005, 45(2): 258-263

[4] LaMarcaB.D., GilbertJ., GrangerJ.P., et al.. Recent progress toward the Understanding of the pathophysiology of hypertension during preeclampsia. Hypertension, 2008, 51(4): 982-988

[5] GermainA.M., RomanikM.C., GuerraI., et al.. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events?. Hypertension, 2007, 49(1): 90-95

[6] StillmanI.E., KarumanchiS.A.. The glomerular injury of preeclampsia. J Am Soc Nephrol, 2007, 18(8): 2281-2284

[7] DeenW.M.. What determines glomerular capillary permeability?. J Clin Invest, 2004, 114(10): 1412-1414

[8] TsatsarisV., GoffinF., MunautC., et al.. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endo Meta, 2003, 88(11): 5555-5563

[9] MaynardS.E., MinJ.Y., KarumanchiS.A., et al.. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest, 2003, 111(5): 649-658

[10] YelumalaiS., MuniandyS., OmarS.Z., et al.. Pregnancyinduced hypertension and preeclampsia: Levels of angiogenic factors in Malaysian women. J Clin Biochem Nutr, 2010, 47(3): 191-197

[11] AsanumaK., Yanagida-AsanumaE., TakagiM., et al.. The role of podocytes in proteinuria. Nephrology (Carlton), 2007, 12(3): 15-20

[12] PatrakkaJ., TryggvasonK.. New insights into the role of podocytes in proteinuria. Nat Rev Nephrol, 2009, 5(8): 463-468

[13] GarovicV.D., WagnerS.J., PetrovicL.M., et al.. Glumerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant, 2007, 22(4): 1136-1143

[14] CollinoF., BussolatiB., GerbaudoE., et al.. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol, 2008, 294(5): 1185-1194

[15] SatchellS.C., TasmanC.H., SinghA., et al.. Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int, 2006, 69(9): 1633-1640

[16] van SettenP.A., van HinsberghV.W., van der VeldenT.J., et al.. Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int, 1997, 51(4): 1245-1256

[17] ShibuyaM.. Structure and dual function of vascular endothelial growth factor receptor-1(Flt-1). Int J Biochem Cell Bio, 2001, 3(4): 409-420

[18] LevineR.J., MaynardS.E., QianC., et al.. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med, 2004, 350(7): 672-683

[19] PowersR.W., RobertsJ.M., CooperK.M., et al.. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol, 2005, 193(1): 185-191

[20] NakatsukasaH., MasuyamaH., TakamotoN., et al.. Circulating leptin and angiogenic factors in preeclampsia patients. Endocr J, 2008, 55(3): 565-573

[21] KarumanchiS.A., LindheimerM.D.. Advances in the understanding of eclampsia. Curr Hypertens Rep, 2008, 10(4): 305-312

[22] AhmadS., AhmedA.. Antiangiogenic effect of soluble vascular endothelial growth factor receptor-l in placental angiogenesis. Endothelium, 2005, 12(1–2): 89-95

[23] KangD.H., JohnsonR.J.. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens, 2003, 12(1): 43-49

[24] FanL., WakayamaT., YokoyamaS., et al.. Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis. Nephron, 2002, 90(1): 95-102

[25] KangD.H., HughesJ., MazzaliM., et al.. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor Administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol, 2001, 12(7): 1448-1457